[1]龚元川,邵国良.载药微球的理化特性及其在肝癌介入治疗中的应用进展[J].介入放射学杂志,2022,31(06):616-622.
　GONG Yuanchuan,SHAO Guoliang..Physical and chemical properties of drug-eluting beads and its application progress in interventional therapy of hepatocellular carcinoma[J].journal interventional radiology,2022,31(06):616-622.
点击复制

载药微球的理化特性及其在肝癌介入治疗中的应用进展()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
31
期数:
2022年06
页码:
616-622
栏目:
综述
出版日期:
2022-07-31

文章信息/Info

Title:
Physical and chemical properties of drug-eluting beads and its application progress in interventional therapy of hepatocellular carcinoma
作者:
龚元川;  邵国良
Author(s):
GONG Yuanchuan;  SHAO Guoliang.
School of Medicine of Shaoxing University， Shaoxing， Zhejiang Province 312000， China
关键词:
【关键词】 肝癌;  载药微球;  肝动脉化疗栓塞术
文献标志码:
A
摘要:
【摘要】 载药微球化疗栓塞术（DEB- TACE）是不可切除肝癌的一种介入治疗技术，具有栓塞肿瘤血管和缓释化疗药物的双重特性。目前用于临床的载药微球主要有DC/LC Beads微球、HepaSphere微球、CalliSpheres微球以及Tandem微球，它们的理化特性各有不同。本文就上述载药微球的理化特性、临床应用、并发症和相关不足作一综述。

参考文献/References:

［1］ Sottani C， Poggi G， Quaretti P， et al. Serum pharmacokinetics in patients treated with transarterial chemoembolization（TACE） using two types of epirubicin- loaded microspheres［J］. Anticancer Res， 2012， 32： 1769- 1774.
［2］ Lewis AL， Gonzalez MV， Lloyd AW， et al. DC bead： in vitro characterization of a drug- delivery device for transarterial chemoembolization［J］. J Vasc Interv Radiol， 2006， 17： 335- 342.
［3］ Guiu B， Hincapie G， Thompson L， et al. An invitro evaluation of four types of drug- eluting embolics loaded with idarubicin［J］. J Vasc Interv Radiol， 2019， 30： 1303- 1309.
［4］ de Baere T， Plotkin S， Yu R， et al. An in vitro evaluation of four types of drug- eluting microspheres loaded with doxorubicin［J］. J Vasc Interv Radiol， 2016， 27： 1425- 1431.
［5］ van Hooy- Corstjens CS， Saralidze K， Knetsch ML， et al. New intrinsically radiopaque hydrophilic microspheres for embolization： synthesis and characterization［J］. Biomacromolecules， 2008， 9： 84- 90.
［6］ Lakhoo J， Adams R， Dave A， et al. Radiopaque beads loaded with doxorubicin in the treatment of patients with hepatocellular carcinoma： a retrospective， multi- center study［J］. Cancer Treat Res Commun， 2020， 25： 100208.
［7］ Zurstrassen CE， Gireli LPO， Tyng CJ， et al. Safety and efficacy of HepaSphere 50- 100 μm in the treatment of hepatocellular carcinoma［J］. Minim Invasive Ther Allied Technol， 2017， 26：212- 219.
［8］ Lee KH， Liapi EA， Cornell C， et al. Doxorubicin- loaded quadrasphere microspheres： plasma pharmacokinetics and intratumoral drug concentration in an animal model of liver cancer［J］. Cardiovasc Intervent Radiol， 2010， 33： 576- 582.
［9］ Oselkin M， Sedora- Roman NI， Pukenas BA， et al. Loading and elution characteristics of quadrasphere microspheres loaded with bevacizumab［J］. Ther Deliv， 2017， 8： 747- 751.
［10］ Chen Q， Shu L， Sun Y， et al. In vitro drug loading， releasing profiles， and in vivo embolic efficacy and safety evaluation of a novel drug- eluting microsphere（CalliSpheres）［J］. Cancer Biother Radiopharm， 2021［Epub ahead of print］.
［11］ Shi Q， Lu Y， Huang S， et al. Apatinib- loaded CalliSpheres beads for embolization in a rabbit VX2 liver tumor： characterization in vitro， pharmacokinetics and tumor response in vivo［J］. Drug Deliv， 2020， 27： 1301- 1307.
［12］ Han X， Chen Q， Sun Y， et al. Morphology， loadability， and releasing profiles of CalliSpheres microspheres in delivering oxaliplatin： an in vitro study［J］. Technol Cancer Res Treat， 2019， 18： 1533033819877989.
［13］ Tanaka T， Nishiofuku H， Hukuoka Y， et al. Pharmacokinetics and antitumor efficacy of chemoembolization using 40 μm irinotecan- loaded microspheres in a rabbit liver tumor model［J］. J Vasc Interv Radiol， 2014， 25： 1037.e2- 1044.e2.
［14］ Heaysman CL， Phillips GJ， Lloyd AW， et al. Synthesis and characterisation of cationic quaternary ammonium- modified polyvinyl alcohol hydrogel beads as a drug delivery embolisation system［J］. J Mater Sci Mater Med， 2016， 27： 53.
［15］ Kim YW， Kwon JH， Nam SW， et al. Sustained multiple organ ischaemia after transarterial chemoembolization with drug- eluting beads for hepatocellular carcinoma［J］. Exp Ther Med， 2018， 15： 1479- 1483.
［16］ Lencioni R， de Baere T， Burrel M， et al. Transcatheter treatment of hepatocellular carcinoma with doxorubicin- loaded DC Bead（DEBDOX）：technical recommendations［J］. Cardiovasc Intervent Radiol， 2012， 35： 980- 985.
［17］ Chang PY， Huang CC， Hung CH， et al. Multidisciplinary Taiwan consensus recommendations for the use of DEBDOX- TACE in hepatocellular carcinoma treatment［J］. Liver Cancer， 2018， 7： 312- 322.
［18］ Grumme J， Werncke T， Meine TC， et al. Transarterial chemoem- bolization for hepatocellular carcinoma： quality of life， tumour response， safety and survival comparing two types of drug- eluting beads［J］. Abdom Radiol（NY）， 2020， 45： 3326- 3336.
［19］ Yang T， Qin W， Sun X， et al. Efficacy and safety of drug- eluting bead- transcatheter arterial chemoembolization using 100- 300 μm versus 300- 500 μm CalliSpheres microspheres in patients with advanced- stage hepatocellular carcinoma［J］. J Cancer Res Ther， 2020， 16： 1582- 1587.
［20］ Wang CY， Xia JG， Yang ZQ， et al. Transarterial chemoem- bolization with medium- sized doxorubicin- eluting Callisphere is safe and effective for patients with hepatocellular carcinoma［J］. Sci Rep， 2020， 10： 4434.
［21］ Lee SY， Ou HY， Yu CY， et al. Drug- eluting bead transarterial chemoembolization for hepatocellular carcinoma： does size really matter?［J］. Diagn Interv Radiol， 2020， 26： 230- 235.
［22］ Lee KH， Liapi E， Vossen JA， et al. Distribution of Iron oxide- containing embosphere particles after transcatheter arterial embolization in an animal model of liver cancer： evaluation with MR Imaging and implication for therapy［J］. J Vasc Interv Radiol ， 2008， 19： 1490- 1496.
［23］ Ou HY， Wu YN， Yu CY， et al. Transarterial chemoembolization using 100- μm drug- eluting microspheres in patients with hepato- cellular carcinoma： a prospective study and midterm follow- up［J］. J Vasc Interv Radiol， 2020， 31： 1784- 1791.
［24］ Kalva SP， Iqbal SI， Yeddula K， et al. Transarterial chemoem- bolization with doxorubicin- eluting microspheres for inoperable hepatocellular carcinoma［J］. Gastrointest Cancer Res， 2011， 4： 2- 8.
［25］ Bai M， Pan T， Zhou C， et al. Transarterial chemoembolization with pirarubicin- eluting microspheres in patients with unresectable hepatocellular carcinoma： preliminary results［J］. J Intervent Med， 2019， 2： 69- 77.
［26］ Malagari K， Pomoni M， Moschouris H， et al. Chemoembolization of hepatocellular carcinoma with HepaSphere 30- 60 μm. Safety and efficacy study［J］. Cardiovasc Intervent Radiol， 2014， 37： 165- 175.
［27］ Bishay VL， Maglione K， Khanna R， et al. Chemoembolization with drug- eluting microspheres（DEM- TACE） for hepatocellular carcinoma： single- center review of safety and efficacy［J］. J Hepatocell Carcinoma， 2014， 1： 187- 193.
［28］ Sun J， Zhou G， Xie X， et al. Efficacy and safety of drug- eluting beads transarterial chemoembolization by CalliSpheres?誖in 275 hepatocellular carcinoma patients： results from the Chinese CalliSpheres?誖 transarterial chemoembolization in liver cancer （CTILC） study［J］. Oncol Res， 2020， 28： 75- 94.
［29］ Peng Z， Cao G， Hou Q， et al. The comprehensive analysis of efficacy and safety of CalliSpheres?誖 drug- eluting beads transarterial chemoembolization in 367 liver cancer patients： a multiple- center， cohort stud［J］. Oncol Res， 2020， 28： 249- 271.
［30］ Cao WZ， Zhou ZQ， Jiang S， et al. Efficacy and safety of drug- eluting beads for transarterial chemoembolization in patients with advanced hepatocellular carcinoma［J］. Exp Ther Med， 2019， 18： 4625- 4630.
［31］ Albrecht KC， Aschenbach R， Diamantis I， et al. Response rate and safety in patients with hepatocellular carcinoma treated with transarterial chemoembolization using 40- μm doxorubicin- eluting microspheres［J］. J Cancer Res Clin Oncol， 2021， 147： 23- 32.
［32］ Greco G， Cascella T， Facciorusso A， et al. Transarterial chemo-embolization using 40 μm drug eluting beads for hepatocellular carcinoma［J］. World J Radiol， 2017， 9：245- 252.
［33］ Richter G， Radeleff B， Stroszczynski C， et al. Safety and feasibility of chemoembolization with doxorubicin- loaded small calibrated microspheres in patients with hepatocellular carcinoma： results of the MIRACLE Ⅰ prospective multicenter study［J］. Cardiovasc Intervent Radiol， 2018， 41： 587- 593.
［34］ Shi Q， Chen D， Zhou C， et al. Drug- eluting beads versus lipiodol transarterial chemoembolization for the treatment of hypovascular hepatocellular carcinoma： a single- center retrospective study［J］. Cancer Manag Res， 2020， 12： 5461- 5468.
［35］ Zhang ZS， Li HZ， Ma C， et al. Conventional versus drug- eluting beads chemoembolization for infiltrative hepatocellular carcinoma： a comparison of efficacy and safety［J］. BMC Cancer， 2019， 19： 1162.
［36］ Lammer J， Malagari K， Vogl T， et al. Prospective randomized study of doxorubicin- eluting- bead embolization in the treatment of hepatocellular carcinoma： results of the PRECISION Ⅴ study［J］. Cardiovasc Intervent Radiol， 2010， 33： 41- 52.
［37］ Karalli A， Teiler J， Haji M， et al. Comparison of lipiodol infusion and drug- eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real- life setting［J］. Scand J Gastroenterol， 2019， 54： 905- 912.
［38］ Liang B， Xiang H， Ma C， et al. Comparison of chemoem-bolization with CalliSpheres?誖microspheres and conventional chemoembolization in the treatment of hepatocellular carcinoma： a multicenter retrospective study［J］. Cancer Manag Res， 2020， 12： 941- 956.
［39］ Lee M， Chung JW， Lee KH， et al. Korean multicenter registry of transcatheter arterial chemoembolization with drug- eluting embolic agents for nodular hepatocellular carcinomas： six- month outcome analysis［J］. J Vasc Interv Radiol， 2017， 28：502- 512.
［40］ Sattler T， Bredt C， Surwald S， et al. Efficacy and safety of drug eluting bead TACE with microspheres ＜150 μm for the treatment of hepatocellular carcinoma［J］. Anticancer Res， 2018， 38： 1025- 1032.
［41］ 朱孟超，张庆桥，徐 浩，等． CalliSpheres载药微球治疗原发性肝癌并发肝脓肿4例分析［J］． 介入放射学杂志， 2020， 29：939- 941．
［42］ Orlacchio A， Chegai F， Francioso S， et al. Repeated transarterial chemoembolization with degradable starch microspheres（DSMs- TACE） of unresectable hepatocellular carcinoma： a prospective pilot study［J］. Curr Med Imaging Rev， 2018，14：637- 645.
［43］ Shi B， Zhang B， Zhang Y， et al. Multifunctional gap- enhanced Raman tags for preoperative and intraoperative cancer imaging［J］. Acta Biomater， 2020， 104： 210- 220.
［44］ Fuchs K， Bize PE， Denys A， et al. Sunitinib- eluting beads for chemoembolization： methods for in vitro evaluation of drug release［J］. Int J Pharm， 2015， 482： 68- 74.

相似文献/References:

[1]张　　　磊,陆骊工,李　　　勇,等.门静脉支架联合肝动脉化疗栓塞治疗肝癌伴门静脉癌栓的临床研究[J].介入放射学杂志,2011,(12):968.
　ZHANG Lei,LU Li-gong,LI Yong,et al.Portal vein stent placement combined with TACE for the treatment of hepatocellular carcinoma associated with tumor thrombus in portal vein[J].journal interventional radiology,2011,(06):968.
[2]敖 劲,张跃伟,徐 克. 明胶海绵微粒经动脉栓塞治疗原发性肝癌的研究现状[J].介入放射学杂志,2011,(12):1010.
　AO Jin,ZHANG Yue-wei,XU Ke..Gelatin sponge particle used as an embolic agent in transcatheter arterial chemoembolization treatment for primary hepatocellular carcinoma: its current situation in research[J].journal interventional radiology,2011,(06):1010.
[3]杜丹丹,吕维富. 肝癌射频消融后的影像学评价[J].介入放射学杂志,2012,(01):75.
　DU Dan dan,Lv Wei fu..Imaging evaluation of liver cancer after radiofrequency ablation therapy[J].journal interventional radiology,2012,(06):75.
[4]赵 艳,韩国宏,白 苇,等. 药物缓释微球肝动脉化疗栓塞治疗肝癌研究进展[J].介入放射学杂志,2012,(01):78.
　ZHAO Yan,HAN Guo-hong,BAI Wei,et al.Transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma: its research progress[J].journal interventional radiology,2012,(06):78.
[5]帕哈尔丁·白克热,杨树法,黄伍奎,等.肝动脉化疗栓塞联合射频消融术治疗３０例原发性大肝癌的疗效评价[J].介入放射学杂志,2012,(04):322.
　,,et al.ＴＡＣＥ ｃｏｍｂｉｎｅｄ ｗｉｔｈ ｒａｄｉｏｆｒｅｑｕｅｎｃｙ ａｂｌａｔｉｏｎ ｆｏｒ ｍａｓｓｉｖｅ ｐｒｉｍａｒｙ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ： ａ ｃｌｉｎｉｃａｌ ｔｈｅｒａｐｅｕｔｉｃ ｅｖａｌｕａｔｉｏｎ [J].journal interventional radiology,2012,(06):322.
[6]杨永波,程红岩.肝动脉化疗栓塞治疗中碘油用量的现状与研究进展[J].介入放射学杂志,2012,(04):348.
　.Ｔｈｅ ｖｏｌｕｍｅ ｏｆ Ｌｉｐｉｏｄｏｌ ｕｓｅｄ ｉｎ ＴＡＣＥ： ｉｔｓ ｃｕｒｒｅｎｔ ｓｉｔｕａｔｉｏｎ ａｎｄ ｒｅｓｅａｒｃｈ ｐｒｏｇｒｅｓｓ [J].journal interventional radiology,2012,(06):348.
[7]何海涛,刘 圣,刘建秦,等. 肝癌TACE术并发脑碘油栓塞二例并文献复习[J].介入放射学杂志,2012,(08):682.
　HE Hai- tao,LIU sheng,LIU Jian- qing,et al. Cerebral Lipiodol embolism occurred after transcatheter arterial chemoembolization for hepatocellular carcinoma: report of two cases with literature review[J].journal interventional radiology,2012,(06):682.
[8]冉 琳,任伯绪. 125I粒子组织间近距离放射治疗肝癌的现状与进展[J].介入放射学杂志,2012,(10):876.
　RAN Lin,REN Bo- xu.. 125I radioactive seeds brachytherapy for hepatocellular carcinomas： its present situation and research progress[J].journal interventional radiology,2012,(06):876.
[9]罗中华,秦 勉,张学昕,等.原发性肝癌合并下腔静脉及右心房癌栓的动脉内化疗栓塞治疗[J].介入放射学杂志,2012,(12):1035.
　LUO Zhong? hua,QIN Mian,ZHANG Xue? xin,et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma complicated by tumor thrombus in inferior vena cava and right atrium[J].journal interventional radiology,2012,(06):1035.
[10]徐光如,张明辉,朱红星,等.磁共振ADC值评价肝硬化合并肝癌介入治疗后肝功能储备的初步研究[J].介入放射学杂志,2013,(01):36.
　XU Guang? ru,ZHANG Ming? hui,ZHU Hong? xing,et al. The application of MR?蛳 ADC value in evaluating the liver function reserve in patients with cirrhosis complicated by hepatic cancer after interventional treatment： a preliminary study[J].journal interventional radiology,2013,(06):36.
[11]翟 越,潘文秋,赵 卫,等.CalliSpheres联合阿帕替尼治疗肝癌的安全性和有效性[J].介入放射学杂志,2020,29(05):462.
　ZHAI Yue,PAN Wenqiu,ZHAO Wei,et al.The safety and effectiveness of CalliSpheres combined with apatinib for the treatment of hepatocellular carcinoma[J].journal interventional radiology,2020,29(06):462.

备注/Memo

备注/Memo:
（收稿日期：2021- 04- 12）
（本文编辑：俞瑞纲）
更新日期/Last Update: 2022-07-29